Can Fite Biopharma Ltd Cash Flow Conversion Efficiency

Latest as of June 2025: -0.568x

Can Fite Biopharma Ltd cash flow conversion efficiency. Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) has a cash flow conversion efficiency ratio of -0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.38 Million ≈ $-6.37K USD) by net assets (ILA4.18 Million ≈ $11.22K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Can Fite Biopharma Ltd (2010–2025)

Cash flow conversion efficiency of Can Fite Biopharma Ltd from 2010 to 2025. This chart illustrates how Can Fite Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Can Fite Biopharma Ltd share price for real-time trading data and today's change.

Can Fite Biopharma Ltd Cash Flow Conversion Ratio Explained

Can Fite Biopharma Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Can Fite Biopharma Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Can Fite Biopharma Ltd ranked by their cash flow conversion efficiency. Also see Can Fite Biopharma Ltd stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Nigbas Nigde Beton Sanayi ve Ticaret AS IS:NIBAS	-0.054x
Lavoro Limited Class A Ordinary Shares NASDAQ:LVRO	-0.676x
Silver Valley Metals Corp V:SILV	-0.070x
Century Global Commodities Corp TO:CNT	-0.047x
Bekasi Asri Pemula Tbk JK:BAPA	-0.003x
EMU NL AU:EMU	-0.047x
Oriental Culture Holding Ltd NASDAQ:OCG	0.009x
Argeo AS OL:ARGEO	-0.020x

Annual Cash Flow Conversion Efficiency for Can Fite Biopharma Ltd (2010–2025)

The table below shows the annual cash flow conversion efficiency of Can Fite Biopharma Ltd from 2010 to 2025. Review Can Fite Biopharma Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	ILA5.59 Million ≈ $15.00K	ILA-9.69 Million ≈ $-25.97K	-1.732x	-23.28%
2024-12-31	ILA5.44 Million ≈ $14.57K	ILA-7.64 Million ≈ $-20.47K	-1.405x	-3.92%
2023-12-31	ILA6.24 Million ≈ $16.74K	ILA-8.44 Million ≈ $-22.63K	-1.352x	+44.03%
2022-12-31	ILA4.47 Million ≈ $11.99K	ILA-10.80 Million ≈ $-28.96K	-2.415x	-252.36%
2021-12-31	ILA14.38 Million ≈ $38.56K	ILA-9.86 Million ≈ $-26.43K	-0.685x	+65.49%
2020-12-31	ILA6.07 Million ≈ $16.28K	ILA-12.06 Million ≈ $-32.34K	-1.986x	+55.24%
2019-12-31	ILA2.44 Million ≈ $6.55K	ILA-10.83 Million ≈ $-29.05K	-4.437x	-221.93%
2018-12-31	ILA3.02 Million ≈ $8.08K	ILA-4.16 Million ≈ $-11.14K	-1.378x	+55.81%
2017-12-31	ILA3.05 Million ≈ $8.19K	ILA-9.52 Million ≈ $-25.53K	-3.118x	-35.33%
2016-12-31	ILA3.87 Million ≈ $10.39K	ILA-8.93 Million ≈ $-23.93K	-2.304x	-417.41%
2015-12-31	ILA10.44 Million ≈ $28.00K	ILA-4.65 Million ≈ $-12.47K	-0.445x	+58.32%
2014-12-31	ILA6.86 Million ≈ $18.38K	ILA-7.33 Million ≈ $-19.64K	-1.069x	+44.80%
2013-12-31	ILA4.46 Million ≈ $11.95K	ILA-8.63 Million ≈ $-23.14K	-1.936x	-131.52%
2012-12-31	ILA-707.99K ≈ $-1.90K	ILA-4.35 Million ≈ $-11.66K	6.141x	+467.80%
2011-12-31	ILA3.29 Million ≈ $8.82K	ILA-5.50 Million ≈ $-14.73K	-1.670x	-497.22%
2010-12-31	ILA13.07 Million ≈ $35.05K	ILA-3.65 Million ≈ $-9.80K	-0.280x	--

About Can Fite Biopharma Ltd

TA:CANF Israel Biotechnology

Market Cap

$2.99 Million

ILA1.11 Billion ILA

Market Cap Rank

#29435 Global

#425 in Israel

Share Price

ILA260.00

Change (1 day)

+0.00%

52-Week Range

ILA1.00 - ILA1500.00

All Time High

ILA1500.00